EASL Congress 2026 活動報告
2026年5月27日（水）～5月30日（土）にかけて、スペイン・バルセロナのFira BarcelonaにてEASL Congress 2026（European Association for the Study of the Liver） が開催されました。横浜市立大学医学部肝胆膵消化器病学教室からは米田正人医師、岩城慶大医師、ならびに国際医療福祉大学熱海病院病院長の中島淳医師が現地に参加いたしました。
筆頭発表演題
Dose-dependent efficacy and renal safety of pemafibrate in patients with MASLD: a multicenter randomized controlled trial.
Iwaki M, Kobayashi T, Nogami A, Imajo K, Nagai K, Sakai E, Nakada Y, Kurihashi T, Tobita H, Sato S, Yamaguchi Y, Kawata K, Matsushita M, Seko Y, Iwasa M, Kawanaka M, Maeda K, Furuta K, Tamaki N, Kawaguchi A, Takahashi H, Yoneda M, Nakajima A.
Efficacy and safety of semaglutide 2.4 mg in the Japanese subgroup of the essence.
Nakajima A, Okanoue T, Hiasa Y, Takahashi H, Belloum A, Kosaka N, Nishida T, Sanyal AJ.
【岩城慶大医師のコメント】
このたび、スペイン・バルセロナで開催されたEASL Congress 2026（European Association for the Study of the Liver）に参加し、研究成果を発表いたしました。
私は、高トリグリセリド血症を合併したMASLD患者を対象とした多施設共同無作為化比較試験（PRESENT study）の結果を報告し、他の研究者との意見交換を通じて有意義な知見を得ることができました。
EASL Congressでは、MASLD領域を中心に数多くの革新的な研究成果が発表され、世界の研究動向や最新の知見に直接触れる貴重な機会となりました。特に薬物療法の分野では、第Ⅱ相・第Ⅲ相臨床試験の結果が相次いで報告され、MASLD診療が新たな時代を迎えつつあることを強く実感しました。
今回得られた知見を今後の研究活動および日常診療に生かし、エビデンスの創出と肝疾患診療の発展に貢献してまいります。
期間中に留守を支えてくださった肝臓グループの皆様にも、心より感謝申し上げます。
共著演題：15演題
■Prognostic Performance of Non-Invasive Risk Models for Major Adverse Liver Outcomes in MASLD: An Individual Participant Data Meta-analysis．
Appiah E, Paudel R, Strandberg R, Akbari C, Padur Aithal G, Berzigotti A, Boursier J, Bugianesi E, Chan W-K, Cassinotto C, Cobbold J, de Lédinghen V, van Dijk A-M, Hirooka M, Holleboom AG, Karlas T, Lee DH, Lupsor-Platon M, Mahadeva S, Mendoza YP, Nakajima A, Noureddin M, Palaniyappan N, Petta S, Shima T, Shalimar, Stauber RE, Staufer K, Tsochatzis E, Truong E, Wiegand J, Wong VW-S, Yoneda M, Zheng M-H, Pavlides M, Hagström H.
■Simplified metabolic dysfunction associated fibrosis-5 (sMAF-5) score to identify at-risk liver fibrosis and to predict prognosis．
Van Kleef LA, Jin X, Yip TC-F, Schneider CV, Boursier J, Bugianesi E, Chan WK, Goh G, Kim SU, Yoneda M, Newsome PN, Petta S, Romero-Gomez M, Sanyal AJ, Zheng M-H, Hagström H, Calleja J-L, Tsochatzis E, de Ledinghen V, Fan J, Janssen HLA, Francque SM, Wong VW-S, Brouwer WP.
■DM-LRE score: gradient boosting machine (GBM)-based machine learning model in predicting liver-related events (LREs) in type 2 diabetes mellitus (T2DM)．
Song SJ, Wong VW-S, Wong GL-H, Lai JC-T, Kim SU, Petta S, Bugianesi E, Yoneda M, Zheng M-H, Romero-Gómez M, Tsochatzis E, Newsome PN, Hagström H, Goh GBB, Chan WK, Calleja Panero JL, Boursier J, Sanyal AJ, Fan J-G, Castera L, de Lédinghen V, Yip TC-F.
■Machine learning prediction of liver fibrosis in patients with metabolic dysfunction associated steatotic liver disease (MASLD)．
Pennisi G, Petta S, Celsa C, Messaoudi S, Tsochatzis E, Bugianesi E, Yoneda M, Zheng M-H, Hagström H, Boursier J, Calleja Panero JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Ledinghen V, Newsome P, Fan J-G, Castera L, Lai M, Fournier-Poizat C, Wong GL-H, Armandi A, Nakajima A, Liu W-Y, Shang Y, de Saint-Loup M, Llop Herrera E, Teh KKJ, Lara-Romero C, Asgharpour A, Chan SWM, Romero-Gómez M, Lin H, Kim SU, Yip TC-F, Calvaruso V, Lai JC-T, Yang B, Lee HW, Di Maria G, Enea M, Contino S, Wong VW-S, Cirrincione G, Cammà C.
■Prognostic significance of a 5 kPa absolute change in liver stiffness measurements (LSM) to predict liver-related events in patients with compensated advanced metabolic dysfunction-associated steatotic liver disease (MASLD)．
Jin X, Peng N, Lin H, Lee HW, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng M-H, Hagström H, Boursier J, Calleja Panero JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan J-G, Castera L, Wong GL-H, Pennisi G, Armandi A, Nakajima A, Liu W-Y, Shang Y, de Saint-Loup M, Llop Herrera E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Lannes A, Romero-Gómez M, Kim SU, Wong VW-S, Loomba R, Yip TC-F.
■Prognostic performance of liver stiffness changes in patients with biopsy-proven cirrhosis secondary to metabolic dysfunction-associated steatohepatitis．
Lai JC-T, Yang B, Lee HW, Lin H, Tsochatzis E, Petta S, Bugianesi E, Yoneda M, Zheng M-H, Hagström H, Boursier J, Calleja Panero JL, Goh GBB, Chan WK, Gallego-Durán R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan J-G, Castera L, Lai M, Fournier-Poizat C, Wong GL-H, Zoncapè M, Pennisi G, Armandi A, Nakajima A, Liu W-Y, Shang Y, de Saint-Loup M, Llop Herrera E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan SWM, Lannes A, MacIas R, Romero-Gómez M, Kim SU, Wong VW-S, Yip TC-F.
■A multicentre multistate modelling on the natural history of liver decompensation．
Tan EXX, Tang NSY, Syn N, Huang DQ, Kulkarni AV, Zheng M-H, Chen VL, Rattananukrom C, Lai JC-T, Wijarnpreecha K, Kumar R, Kaewdech A, Ueno M, Roy A, Nakamura T, Gao Y, Yoneda M, Seko Y, Kimura T, Noureddin M, Shadab M, Siddiqui H, Takahashi H, Cheng HN, Muthiah MD.
■Hepatocellular carcinoma (HCC) in patients with biopsy proven metabolic dysfunction.
Younossi ZM, Huang D, Nakajima A, Pinto Oliveira C, Petta S, Hagström H, Sebastiani G, Goh GBB, Ekstedt M, Arab JP, Crespo J, Castera L, Kakizaki S, Kim SU, Wong VW-S, Tsochatzis E, Valsan A, Villela-Nogueira CA, Papatheodoridis G, Francque S, Treeprasertsuk S, D’Ambrosio R, Roberts S, Yilmaz Y, Shalimar, Chan WK, Lai JC-T, Abreu E, Aggarwal A, de Avila L, Stepanova M.
■Clinical profile, histologic features, non-invasive test accuracy, and long-term outcomes of lean metabolic dysfunction associated steatotic liver disease (MASLD): insights from the global masld project.
Younossi ZM, de Avila L, Petta S, Hagström H, Kim SU, Nakajima A, Crespo J, Castera L, Alkhouri N, Zheng M-H, Treeprasertsuk S, Ananchuensook P, Shalimar, Tsochatzis E, Shenoy KT, Mohan L, Fan J-G, Roberts S, Alswat KA, Wong VW-S, Yilmaz Y, Dunn W, Francque S, Cordie A, Yu M-L, Ekstedt M, Goh GBB, Pinto Oliveira C, Pessoa M, Chan WK, Castellanos Fernández MI, Duseja AK, Arab JP, Papatheodoridis G, Sebastiani G, Villela-Nogueira CA, D’Ambrosio R, Lampertico P, Al Naamani K, Holleboom AG, Valsan A, Venu A, El-Kassas M, Pennisi G, Shang Y, Liu W-Y, Lee HW, Kobayashi T, Kakizaki S, Caussy C, Pearlman B, Iruzubieta P, Nadeem R, Cinque F, Papatheodoridi M, Zoncapè M, Yang R-X, Song SJ, Dunn N, Gadi Z, Yeh M-L, Teh KKJ, Mahadeva S, Gonzalez Fabian L, Almohsen A, Leite N, Pugliese N, Vessby J, Xie C, Choudhary NS, Friend E, Poca M, Kawaguchi T, Russo FP, Gadano A, Diaz LA, Singal AK, Ségrestin B, Gunn N, Mauricio D, Arrese M, Fracanzani AL, Lombardi R, Aghemo A, Lam B, Khoja B, Almuhaidib S, Alqahtani S, Racila A, Stepanova M.
■Application of fibrosis tests and hepatocellular carcinoma prediction scores in metabolic dysfunction-associated steatotic liver disease.
Lin H, Wang H, Zeng X, Yang F, Lai JC-T, Lee HW, Sanyal AJ, Nakajima A, Bugianesi E, Tsochatzis E, Goh GBB, Hagström H, Boursier J, Calleja Panero JL, Romero-Gómez M, Zheng M-H, Newsome P, Petta S, de Lédinghen V, Chan WK, Chen L, Chang L, Wang Y, Qi X, Liu C, Yoneda M, Fan J-G, Castera L, Lai M, Wong GL-H, Pennisi G, Armandi A, Liu W-Y, Shang Y, Yip TC-F, Kim SU, Wong VW-S.
■Long-term liver-related outcomes in asian and caucasian patients with MASLD: evidence from a large multicentric observational study.
Armandi A, Fariselli P, Caviglia GP, Lee HW, Yoneda M, Zheng M-H, Petta S, Tsochatzis E, Boursier J, Calleja Panero JL, Hagström H, Romero-Gómez M, Castera L, Sanyal AJ, de Lédinghen V, Newsome P, Lin H, Yip TC-F, Goh GBB, Chan WK, Gallego-Durán R, Fan J-G, Lai M, Fournier-Poizat C, Wong GL-H, Mellemkjær A, Zoncapè M, Pennisi G, Nakajima A, Liu W-Y, Shang Y, de Saint-Loup M, Llop Herrera E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan SWM, Canivet CM, Kim SU, Wong VW-S, Bugianesi E.
■A PNPLA3 antisense oligonucleotide, AZD2693, for the treatment of MASH in I148M homozygous participants: results from the phase 2b FORTUNA study.
Loomba R, Nakajima A, Arrese M, Bugianesi E, Pachori A, Fjellstrom O, Sarv J, Liljeblad M, Shruti K, Armisen J, Hansen L, Wong VW-S.
■Multimodal analysis bridges liver histological features identified by AI based digital histology tools and -omic signatures in a Japanese MASH cohort.
Hou R, Ebrahimi A, Gupta V, Yashiro H, Chuang J-C, Derdak Z, Farahmand S, Aishima S, Hyogo H, Eguchi Y, Murakami E, Yoneda M, Wennbo H, Thakker P, Allan B, Takahashi H, Nakajima A, Paraskevopoulou MD, Saha B.
■Liver fibrosis is the only predictor of adverse outcomes: time to remove metabolic dysfunction associated steatohepatitis (MASH) resolution as a clinical trial endpoint.
Younossi ZM, Yu M-L, de Avila L, Petta S, Hagström H, Kim SU, Nakajima A, Crespo J, Castera L, Alkhouri N, Zheng M-H, Treeprasertsuk S, Ananchuensook P, Shalimar, Tsochatzis E, Shenoy KT, Mohan L, Fan J-G, Roberts S, Alswat KA, Wong VW-S, Yilmaz Y, Dunn W, Francque S, Cordie A, Alqahtani S, Ekstedt M, Goh GBB, Pinto Oliveira C, Pessoa M, Chan WK, Castellanos Fernández MI, Duseja AK, Arab JP, Papatheodoridis G, Sebastiani G, Villela-Nogueira CA, D’Ambrosio R, Lampertico P, Al Naamani K, Holleboom AG, Valsan A, Venu A, El-Kassas M, Pennisi G, Shang Y, Liu W-Y, Lee HW, Kobayashi T, Kakizaki S, Caussy C, Pearlman B, Iruzubieta P, Nadeem R, Cinque F, Papatheodoridi M, Zoncapè M, Yang R-X, Song SJ, Dunn N, Gadi Z, Yeh M-L, Teh KKJ, Mahadeva S, Gonzalez Fabian L, Almohsen A, Leite N, Pugliese N, Vessby J, Xie C, Choudhary NS, Friend E, Poca M, Kawaguchi T, Russo FP, Gadano A, Diaz LA, Singal AK, Ségrestin B, Gunn N, Mauricio D, Arrese M, Fracanzani AL, Lombardi R, Aghemo A, Zelber-Sagi S, Lam B, Racila A, Stepanova M.
■Routine markers for monitoring liver stiffness in patients with MASLD and low-risk fibrosis.
Roeren M, Boursier J, Bugianesi E, Chan WK, Fan JG, Goh GBB, Kim SU, de Lédinghen V, Yoneda M, Newsome PN, Petta S, Romero‑Gómez M, Sanyal AJ, Zheng MH, Calleja Panero JL, Tsochatzis E, Yip TCF, Wong VWS, Hagström H, Shang Y.
